IRIS
GOBBI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.171
EU - Europa 827
AS - Asia 606
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
SA - Sud America 1
Totale 2.614
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.166
CN - Cina 583
IE - Irlanda 272
UA - Ucraina 146
FI - Finlandia 128
DE - Germania 94
SE - Svezia 75
IT - Italia 41
GB - Regno Unito 34
SG - Singapore 13
BE - Belgio 12
CZ - Repubblica Ceca 8
EU - Europa 6
FR - Francia 6
CA - Canada 5
IN - India 4
AU - Australia 3
MK - Macedonia 3
NL - Olanda 2
RO - Romania 2
TR - Turchia 2
BR - Brasile 1
DK - Danimarca 1
GR - Grecia 1
JP - Giappone 1
MY - Malesia 1
PT - Portogallo 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 2.614
Salva come PNG Salva come JPEG
Città #
Chandler 298
Dublin 272
Jacksonville 215
Nanjing 178
Beijing 81
Ashburn 73
Nanchang 69
Ann Arbor 59
Lawrence 49
Princeton 49
Wilmington 46
Hebei 45
Jiaxing 40
Medford 40
Shenyang 39
Helsinki 37
Changsha 34
Boardman 25
Hangzhou 24
Tianjin 24
New York 18
Shanghai 13
Brussels 12
Des Moines 12
Milan 11
Woodbridge 11
Seattle 10
Brno 8
Norwalk 8
Fairfield 7
Kunming 6
Pavia 6
Los Angeles 5
Munich 5
Singapore 5
Verona 5
Guangzhou 4
Houston 4
San Genesio Ed Uniti 4
Andover 3
Cambridge 3
Haikou 3
Jinan 3
Ningbo 3
Orange 3
Washington 3
Borås 2
Chicago 2
Dallas 2
Dearborn 2
Falkenstein 2
Lanzhou 2
Orlando 2
Philadelphia 2
San Francisco 2
Taizhou 2
Toronto 2
Albert Park 1
Atlanta 1
Auburn Hills 1
Berlin 1
Boston 1
Bridgeport 1
Bucharest 1
Canberra 1
Cedar Knolls 1
Cupertino 1
Edmonton 1
Henderson 1
Hyderabad 1
Jinshan 1
Kharkov 1
Las Vegas 1
Lonigo 1
Markham 1
Modena 1
Monsummano Terme 1
Naples 1
Pune 1
Riyadh 1
Rockville 1
Selangor 1
Southend 1
Tokyo 1
Zhengzhou 1
Totale 1.922
Salva come PNG Salva come JPEG
Nome #
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system 76
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 76
International prognostic scoring system for Waldenstrom macroglobulinemia 73
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 73
Chemoresistance as a function of the pre-therapy tumor burden and the chemotherapy regimen administered. Differences observed with two current chemotherapy regimens for advanced Hodgkin lymphoma 73
Pamidronate versus observation in asymptomatic myeloma: final results with long follow-up of a randomized study 68
The clinical value of tumor burden at diagnosis in Hodgkin lymphoma 67
[Idiopathic myelodysplastic syndromes. A caseload contribution]. 67
Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients 66
Tumor burden in Hodgkin’s lymphoma: much more than the best prognostic factor. 66
The prognosis of patients with liver metastases from colorectal cancer still depends on anatomical presentation more than on treatments 66
New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. 65
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 62
Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters 61
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 60
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 60
Long-term follow-up analysis of HD9601 trial comparing ABVD vs. Stanford V vs. MOPPEBVCAD in patients with newly diagnosed advanced-stage Hodgkin lymphoma. A study from the Intergruppo Italiano Linfomi (IIL). 60
Changing clinical presentation of multiple myeloma. 60
Tumor burden predicts treatment resistance in patients with early unfavorable or advanced-stage Hodgkin Lymphoma treated with ABVD and radiotherapy. 59
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. 59
Long-term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with ProMECE-CytaBOM plus involved-field radiation therapy: a study of the Gruppo Italiano Studio Linfomi. 59
R-CHOP vs. R-mini-CEOP for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL). 58
Improving the AJCC/TNM Classification for use in early gastric cancer 58
Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy 58
Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. 57
International prognostic scoring system for Waldenstrom macroglobulinemia. 56
Tumor burden at diagnosis is the main clinical predictor of cell resistance in patients with early-stage, favorable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. 54
Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells 54
What has happened to VBM (vinblastine, bleomycin and methotrexate) chemotherapy for early-stage Hodgkin lymphoma ? 52
Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact 52
Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study 51
A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. 50
Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma. 49
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation 49
Chronic granulocytic leukemia. A retrospective study of 91 cases. I. Hemogram at diagnosis and research of prognostic factors. 48
Erratum to: Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study (Intern Emerg Med, (2014), 9, (861-870), DOI 10.1007/s11739-014-1096-1) 47
Prognostic validation of the international classification of immunoglobulin M gammopathies: A survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? 47
How I treat enteropathy-associated T-cell lymphoma 46
Hodgkin lymphoma. 45
Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes 43
Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy. 42
Reed-Sternberg cell leukaemia. 41
Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati [Avascular jaw osteonecrosis associated with bisphophonate therapy]. 41
The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer 40
Natural history of idiopathic refractory sideroblastic anemia. 37
Prognostic factors in symptomatic Waldenstrom's macroglobulinemia 36
Low incidence but poor prognosis of complicated coeliac disease in four Italian centres. 34
Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility 26
Prognostic factors in non-Hodgkin's lymphomas 24
Totale 2.671
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.612
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.612
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020692 203 267 0 29 2 31 6 33 1 75 45 0
2020/2021314 42 27 4 30 2 40 3 52 13 51 40 10
2021/2022240 5 3 2 4 7 2 6 15 6 11 40 139
2022/2023790 76 76 9 67 81 76 2 56 316 6 16 9
2023/2024235 44 39 10 17 19 56 3 28 1 5 4 9
2024/202526 26 0 0 0 0 0 0 0 0 0 0 0
Totale 2.671